Search for: "Anda Pharmaceuticals, Inc"
Results 241 - 260
of 607
Sorted by Relevance
|
Sort by Date
31 Jul 2014, 8:43 pm
Cubist Pharmaceuticals Inc. v. [read post]
19 Jul 2015, 9:59 pm
Akorn Inc. 1:15-cv-00474; filed June 11, 2015 in the District Court of Delaware Infringement of U.S. [read post]
23 Apr 2014, 9:59 pm
.; Cipla USA Inc. [read post]
9 Nov 2014, 9:38 pm
.; Takeda Pharmaceuticals USA Inc. [read post]
12 Jan 2014, 6:36 pm
.; Micro Labs USA Inc. [read post]
30 Aug 2019, 4:15 am
’s (“Actavis’s”) generic Abbreviated New Drug Application (“ANDA”) product infringed claims of patents owned by Nalpropion Pharmaceuticals (“Nalpropion”) and that the asserted claims were not invalid. [read post]
8 Aug 2010, 8:32 pm
.; Ranbaxy Pharmaceuticals Inc.; Ranbaxy, Inc.; Ethypharm S.A. [read post]
3 Oct 2015, 10:23 am
From SPECTRUM PHARMACEUTICALS, INC. v. [read post]
17 Aug 2010, 9:42 am
Teva Pharmaceuticals USA, Inc., C.A. [read post]
28 Sep 2008, 8:48 pm
Pharmaceutical Associates, Inc.3:08-cv-04718; filed September 19. 2008 in the District Court of New Jersey Infringement of U.S. [read post]
FTC and California AG Join in Challenging Reverse Payment Settlements in the Pharmaceutical Industry
6 Mar 2009, 7:03 am
Watson Pharm., Inc. et al., 09-cv-00598 (AHM) ("Watson"). [read post]
30 Nov 2012, 6:00 am
Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE®Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. [read post]
30 Nov 2012, 6:00 am
Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE®Teva Pharmaceutical Industries Ltd. issued a press release last week discussing the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. [read post]
5 Sep 2012, 5:26 am
("Intendis") and Dow Pharmaceutical Sciences, Inc. [read post]
20 May 2016, 6:58 am
" Takeda Pharmaceuticals USA, Inc. v. [read post]
21 May 2012, 9:33 pm
Mylan Pharmaceuticals Inc. 1:12-cv-00523; filed April 26, 2012 in the District Court of Delaware Infringement of U.S. [read post]
4 Apr 2010, 9:55 pm
Endo Pharmaceuticals Inc. 1:10-cv-00261; filed March 31, 2010 in the District Court of Delaware Infringement of U.S. [read post]
17 Mar 2014, 11:03 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited (these three companies are, collectively, "Mylan"); Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE;… [read post]
30 Jun 2014, 10:28 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.;… [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than $400… [read post]
